Table 2. Risk of study outcomes among diabetic patients with advanced chronic kidney disease comparing TZD users vs. nonusers.
| No. of Events | Incidence Rate per 100 Patient-years | Long-term Dialysis | Long-term Dialysis or Death | |||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Type of treatment | Long-term dialysis | Long-term dialysis or death | Long-term dialysis | Long-term dialysis or death | Crude HR (95% CI) | Adjusted HR + (95% CI) | PSM HR (95% CI) | Crude HR (95% CI) | Adjusted HR + (95% CI) | PSM HR (95% CI) |
| TZD nonuser | 7,368 | 9656 | 88.4 | 115.8 | 1 (Ref.) | 1 (Ref.) | 1 (Ref.) | 1 (Ref.) | 1 (Ref.) | 1 (Ref.) |
| (n = 11,126) | ||||||||||
| TZD user | 839 | 1144 | 70.4 | 96.0 | 0.83 (0.78–0.90) | 0.81 (0.75–0.87) | 0.80 (0.74–0.86) | 0.85 (0.80–0.91) | 0.87 (0.81–0.92) | 0.85 (0.80–0.91) |
| (n = 1,224) | ||||||||||
| Pioglitazone | 272 | 377 | 81.0 | 112.3 | 0.91 (0.81–1.03) | 0.84 (0.75–0.95) | 0.84 (0.74–0.95) | 0.97 (0.87–1.07) | 0.96 (0.87–1.07) | 0.94 (0.84–1.05) |
| (n = 470) | ||||||||||
| Rosiglitzone | 537 | 724 | 66.2 | 89.2 | 0.81 (0.74–0.88) | 0.79 (0.72–0.86) | 0.77 (0.70–0.85) | 0.80 (0.75–0.87) | 0.82 (0.76–0.89) | 0.81 (0.75–0.88) |
| (n = 799) | ||||||||||
Abbreviations: CI, confidence interval; HR, hazard ratio; PSM, propensity score matched; TZD, thiazolidinedione.
+A multivariate analysis was adjusted for all variables listed in Table 1.